KR20030038655A - 유효성분의 경구 흡수를 개선하기 위한 미립자 벡터 - Google Patents

유효성분의 경구 흡수를 개선하기 위한 미립자 벡터 Download PDF

Info

Publication number
KR20030038655A
KR20030038655A KR10-2003-7000198A KR20037000198A KR20030038655A KR 20030038655 A KR20030038655 A KR 20030038655A KR 20037000198 A KR20037000198 A KR 20037000198A KR 20030038655 A KR20030038655 A KR 20030038655A
Authority
KR
South Korea
Prior art keywords
heparin
polymer
poly
particulate vector
polymers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR10-2003-7000198A
Other languages
English (en)
Korean (ko)
Inventor
필립쁘 맹성
나딸리 위브히쉬
클라우드 비그네홍
Original Assignee
필립쁘 맹성
나딸리 위브히쉬
클라우드 비그네홍
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 필립쁘 맹성, 나딸리 위브히쉬, 클라우드 비그네홍 filed Critical 필립쁘 맹성
Publication of KR20030038655A publication Critical patent/KR20030038655A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
KR10-2003-7000198A 2000-07-07 2001-07-05 유효성분의 경구 흡수를 개선하기 위한 미립자 벡터 Withdrawn KR20030038655A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR00/08902 2000-07-07
FR0008902A FR2811227A1 (fr) 2000-07-07 2000-07-07 Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs
PCT/FR2001/002159 WO2002003960A1 (fr) 2000-07-07 2001-07-05 Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs

Publications (1)

Publication Number Publication Date
KR20030038655A true KR20030038655A (ko) 2003-05-16

Family

ID=8852251

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2003-7000198A Withdrawn KR20030038655A (ko) 2000-07-07 2001-07-05 유효성분의 경구 흡수를 개선하기 위한 미립자 벡터

Country Status (17)

Country Link
US (1) US8052998B2 (https=)
EP (1) EP1313453B1 (https=)
JP (1) JP5175017B2 (https=)
KR (1) KR20030038655A (https=)
CN (1) CN1440277A (https=)
AT (1) ATE395906T1 (https=)
AU (1) AU2002218745A1 (https=)
BR (1) BRPI0112080B1 (https=)
CA (1) CA2415414C (https=)
DE (1) DE60134147D1 (https=)
DK (1) DK1313453T3 (https=)
ES (1) ES2305121T3 (https=)
FR (1) FR2811227A1 (https=)
MX (1) MXPA03000193A (https=)
PT (1) PT1313453E (https=)
RU (1) RU2003103596A (https=)
WO (1) WO2002003960A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2060253A1 (en) * 2007-11-14 2009-05-20 Laboratorios Farmaceuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
US8257744B2 (en) 2000-07-07 2012-09-04 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
BE1015608A6 (fr) * 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
DE602004003577T2 (de) * 2003-04-17 2007-09-20 Jallal Messadek Flottierende orale Formulierungen mit kontrollierter Freisetzung von Betain
US20060128657A1 (en) * 2003-08-04 2006-06-15 Jallal Messadek Selected betaines and their uses
WO2006088647A1 (en) * 2005-02-17 2006-08-24 Medivas, Llc Polymer particle delivery compositions and methods of use
EP1730516A1 (en) * 2004-03-30 2006-12-13 Pfizer Products Incorporated Method and device for evaluation of pharmaceutical compositions
BE1016128A6 (fr) * 2004-07-22 2006-03-07 Messadek Jallal Combinaisons therapeutiques
WO2006050581A2 (en) * 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
BRPI0610249A2 (pt) * 2005-04-27 2010-06-08 Jallal Messadek associação ou combinação farmacêutica, composição farmacêutica, processo de co-cristalização e o uso de insulina ou análogo de insulina
CA2623239C (en) 2005-09-22 2016-07-12 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
US20100119612A1 (en) * 2007-04-17 2010-05-13 Bend Research, Inc Nanoparticles comprising non-crystalline drug
WO2008135855A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
WO2008135828A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
WO2008135852A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Pharmaceutical compositions comprising nanoparticles and casein
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
EP2162120B1 (en) * 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US20100215747A1 (en) * 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
EP2213282A1 (en) * 2009-01-30 2010-08-04 Laboratorios Farmaceuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
US8802156B2 (en) 2007-11-14 2014-08-12 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
WO2009065193A1 (en) * 2007-11-21 2009-05-28 Jallal Messadek Treatment of aspirin resistance with betaine and/or betaine enriched molasses
US9233078B2 (en) * 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
WO2009073215A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
US9101547B2 (en) * 2011-08-04 2015-08-11 Nano And Advanced Materials Institute Limited Enteric-coated capsule containing cationic nanoparticles for oral insulin delivery
DE102012019029A1 (de) 2012-09-27 2014-03-27 Alf Lamprecht Arzneiformulierungen zur oralen Gabe von therapeutischen Substanzen und Verfahren zur Herstellung
CA3015172A1 (en) 2016-02-18 2017-08-24 Privo Technologies, Inc. Two-stage microparticle-based therapeutic delivery system and method
US20180235899A1 (en) 2017-02-17 2018-08-23 Privo Technologies, Inc. Particle-based multi-layer therapeutic delivery device and method
US10478403B1 (en) 2017-05-03 2019-11-19 Privo Technologies, Inc. Intraoperative topically-applied non-implantable rapid release patch
KR20240041285A (ko) 2021-06-01 2024-03-29 프리보 테크놀로지스, 인코포레이티드 향상된 2단계 미세입자 기반 국소 치료제 전달 시스템

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT397345B (de) * 1990-04-04 1994-03-25 Chemiefaser Lenzing Ag Pharmazeutisches präparat mit verzögerter wirkstofffreisetzung auf basis von hemicellulosen
AU653771B2 (en) * 1991-01-03 1994-10-13 Alkermes Controlled Therapeutics, Inc. Stabilization of proteins by cationic biopolymers
ATE154241T1 (de) * 1991-10-01 1997-06-15 Takeda Chemical Industries Ltd Mikropartikeln-zusammenfassung zur verlängerten freigabe und herstellung derselbe
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
DE4220782A1 (de) * 1992-06-25 1994-01-05 Basf Ag Verfahren zur Herstellung von festen pharmazeutischen Retardformen
US5401516A (en) * 1992-12-21 1995-03-28 Emisphere Technologies, Inc. Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof
GB9412273D0 (en) * 1994-06-18 1994-08-10 Univ Nottingham Administration means
ATE201983T1 (de) * 1995-03-10 2001-06-15 Roche Diagnostics Gmbh Polypeptid-enthaltende pharmazeutische darreichungsformen in form von mikropartikeln und verfahren zu deren herstellung
US5686113A (en) * 1995-03-21 1997-11-11 Temple University Of The Commonwealth System Of Higher Education Microcapsules of predetermined peptide(s) specificity (ies), their preparation and uses
FR2769853B1 (fr) * 1997-10-21 2000-01-28 Prographarm Lab Nouveau procede d'obtention de microspheres et les produits ainsi realises
HK1040910B (en) * 1998-11-12 2009-06-26 Smithkline Beecham Plc Pharmaceutical composition for modified release of an insulin sensitiser and metformin
AU3471400A (en) * 1999-01-19 2000-08-07 Children's Hospital Of Philadelphia, The Compositions and methods for controlled delivery of virus vectors

Also Published As

Publication number Publication date
CA2415414A1 (fr) 2002-01-17
DK1313453T3 (da) 2008-09-22
RU2003103596A (ru) 2004-08-20
ATE395906T1 (de) 2008-06-15
CA2415414C (fr) 2011-08-23
WO2002003960A1 (fr) 2002-01-17
BR0112080A (pt) 2003-05-06
BRPI0112080B1 (pt) 2017-01-24
PT1313453E (pt) 2008-07-16
EP1313453A1 (fr) 2003-05-28
MXPA03000193A (es) 2004-09-13
ES2305121T3 (es) 2008-11-01
EP1313453B1 (fr) 2008-05-21
JP2004502720A (ja) 2004-01-29
AU2002218745A1 (en) 2002-01-21
JP5175017B2 (ja) 2013-04-03
US20050013866A1 (en) 2005-01-20
CN1440277A (zh) 2003-09-03
FR2811227A1 (fr) 2002-01-11
US8052998B2 (en) 2011-11-08
DE60134147D1 (de) 2008-07-03

Similar Documents

Publication Publication Date Title
KR20030038655A (ko) 유효성분의 경구 흡수를 개선하기 위한 미립자 벡터
US8361509B2 (en) Pharmaceutical dosage forms for the release of active compounds
JP2571874B2 (ja) タンパク質マイクロスフェア組成物
US5753234A (en) Single-shot vaccine formulation
Cegnar et al. Cystatin incorporated in poly (lactide-co-glycolide) nanoparticles: development and fundamental studies on preservation of its activity
JPH07502990A (ja) 多相マイクロ球の製造と使用
JPH01216918A (ja) 生理活性物質含有ポリ乳酸系微小球およびその製造法
CN107184954A (zh) 包含格拉默或其药用盐的储药系统
CN116531332B (zh) 基于NETs调控的微血栓靶向脂质体递药系统及其制备方法和应用
WO2002000207A9 (en) The controlled release preparation of insulin and its method
Jiao et al. Preparation and in vitro evaluation of heparin-loaded polymeric nanoparticles
WO2011103382A2 (en) Compositions and methods for inducing angiogenesis
CN102724969A (zh) 第九凝血因子缓释剂型
WO2003099262A1 (en) Process for the production of nanoparticles, wherein low mechanical and sonic energies are used simultaneously
EP2219611B1 (en) Pharmaceutical forms for the release of active compounds
CN1460468A (zh) 改进的包埋蛋白类药物和疫苗的高分子微球的制备方法
RU2647466C1 (ru) Способ получения нативного белка пролонгирующего действия в составе полимерных наносфер и резорбируемых микросфер для доставки
HK1057475A (en) Particulate vectors for improving oral absorption of active principles
KR100202395B1 (ko) 쑥으로부터 추출된 파네실전이 효소저해활성을 갖는 아타노말로이드계 화합물 및 이를 함유하는 조성물
McGinity et al. Preparation and uses of multi-phase microspheres
TWI516275B (zh) 第九凝血因子緩釋劑型
Cai Biodegradable polymer micro-and nanoparticles as protein delivery systems: influence of microparticle morphology and improvement of protein loading capacity of nanoparticles
JP2004513706A (ja) 微粒子の製造方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20030106

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid